title: Prevention of diet-induced hyperlipidemia and obesity by caffeic acid in C57BL/6 mice through regulation of hepatic lipogenesis gene expression.
abstract: This study investigated the influence of phenolic caffeic acid on obesity in mice fed a high fat diet and its underlying mechanisms base on adipose and hepatic lipid lipogenesis. C57BL/6 mice were fed a normal diet or a HFD (20% fat, w/w) with or without caffeic acid (0.02% and 0.08%, w/w) for 6 weeks. The effects of caffeic acid on hyperlipidemia, hyperglycemia, visceral fat accumulation, and related enzyme activities in HFD-mice are examined. The supplementation of caffeic acid significantly lowered body weight, visceral fat mass, plasma GOT and GPT levels, FAS activity, and free fatty acid compared to the HFD group. Caffeic acid also lowered triglyceride and cholesterol concentrations in plasma and liver. Furthermore, we showed that caffeic acid efficiently inhibited cholesterol biosynthesis as evidenced by 3-hydroxy-3-methylglutaryl CoA reductase in the liver. Caffeic acid supplementation suppressed the activity of lipogenesis via sterol regulatory element-binding protein 1 c and its target enzyme fatty acid synthase. In addition, caffeic acid resulted in increased phosphorylation of AMP-activated protein kinase and decreased acetyl carboxylase, a downstream target of AMPK, which are related to fatty acid β-oxidation in the liver. In conclusion, these results indicate that caffeic acid exhibits a significant potential as an antiobesity agent by suppression of lipogenic enzymes and hepatic lipid accumulation.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Cheng-Ching Hospital , Taichung, Taiwan.
authors.forename: Chung-Chia
authors.initials: CC
authors.lastname: Liao
authors.forename: Ting-Tsz
authors.initials: TT
authors.lastname: Ou
authors.forename: Cheng-Hsun
authors.initials: CH
authors.lastname: Wu
authors.forename: Chau-Jong
authors.initials: CJ
authors.lastname: Wang
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000235:genetics / Q000378:metabolism; D050156:Adipogenesis / Q000187:drug effects; D000818:Animals; D002109:Caffeic Acids / Q000008:administration & dosage*; D059305:Diet, High-Fat / Q000009:adverse effects; D006801:Humans; D006949:Hyperlipidemias / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control*; D050155:Lipogenesis / Q000187:drug effects*; D008099:Liver / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000201:enzymology / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control*; D051780:Sterol Regulatory Element Binding Protein 1 / Q000235:genetics / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism
chemical_list: D002109:Caffeic Acids; D051780:Sterol Regulatory Element Binding Protein 1; D014280:Triglycerides; D055372:AMP-Activated Protein Kinases; C040048:caffeic acid